532 / 1084
Post-induction therapy FDG PET
clinically useful in the selection of subsequent therapy?:
identify CR
avoid surgery
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET):
can postchemoradiotherapy FDG-PET predict the utility of resection? Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR,
Mishra G, Isom S, Clark P, Levine EA, Blackstock. J Clin Oncol. 2010;28(31):4714
But: not confirmed in
Utility of (18)F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation. Arnett
AL, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier.
J Thorac Oncol. 2017 Jan;12(1):121-128
Identify non responders:
MUNICON study:metabolic responders had a significantly
better prognosis than did non responders
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the
MUNICON phase II trial.AULordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H,
Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR SOLancet Oncol. 2007;8(9):797